Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD

MLA

Moussab Damlaj, et al. “Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD.” Clinical Lymphoma Myeloma and Leukemia, vol. 20, Oct. 2020, pp. 690–96. EBSCOhost, https://doi.org/10.1016/j.clml.2020.05.012.

APA

Moussab Damlaj, Mohammad Snnallah, Ayman Alhejazi, Bader Alahmari, Mohsen Alzahrani, Razan Bashir, Hind Salama, Ahmed Alaskar, & Inaam Shehab Eddine. (2020). Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD. Clinical Lymphoma Myeloma and Leukemia, 20, 690–696. https://doi.org/10.1016/j.clml.2020.05.012

Chicago

Moussab Damlaj, Mohammad Snnallah, Ayman Alhejazi, Bader Alahmari, Mohsen Alzahrani, Razan Bashir, Hind Salama, Ahmed Alaskar, and Inaam Shehab Eddine. 2020. “Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD.” Clinical Lymphoma Myeloma and Leukemia 20 (October): 690–96. doi:10.1016/j.clml.2020.05.012.